{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"5"}],"title":"Overall Response Rate (Partial Response or Better)"},{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"6"}],"title":"Stable Disease or Progression"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"11"}],"units":"Participants"}],"description":"Very Good PR or greater will be evaluated nine months postrandomization according to International Uniform Response Criteria. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.","groups":[{"description":"All patients will receive 4 cycles of clarithromycin 500mg twice daily on days 1-28, pomalidomide 4 mg daily on days 1 through 21 and dexamethasone orally at a dose of 40 mg daily on days 1, 8, 15, and 22 of each 28-day cycle. Patients randomized to auto-SCT will proceed within 28 days after completion of the 4th cycle of ClaPD to receive melphalan 140mg/m2 or 200mg/m2 (as per institutional guidelines) followed by hematopoietic cell infusion.\n\nPomalidomide\n\nstem cell\n\nClarithromycin","id":"OG000","title":"Clarithromycin + Pomalidomide + Dexamethasone + Stem Cell"},{"description":"All patients will receive 4 cycles of clarithromycin 500mg twice daily on days 1-28 pomalidomide 4 mg daily on days 1 through 21 and dexamethasone orally at a dose of 40 mg daily on days 1, 8, 15, and 22 of each 28 day cycle. Patients assigned to ClaPD alone will receive 5 additional cycles of ClaPD.\n\nPomalidomide\n\nDexamethasone\n\nClarithromycin","id":"OG001","title":"Clarithromycin + Pomalidomide + Dexamethasone Alone"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"at 9 months after the start of treatment","title":"Overall Response Rate","type":"PRIMARY","unitOfMeasure":"Participants"}